SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " mace " 311 found 🔀 AI-powered Shuffle
Opinion: The science that protects our children doesn't take a summer vacation
Connecticut's own biopharmaceutical community has played an important role in advancing vaccine science.
Nancy Mace Unveils Tattoos as She Prepares to Leave Congress
The South Carolina Republican previously discussed getting inked because of "the pain that I need to feel."
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
/PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned...
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
Pace appoints Andy Fenny as president to drive life science growth
Pace, a science and technology company, has appointed Andrew (Andy) Fenny as president of Pace Life Sciences, the organization’s life sciences division, to lead the business into its next phase of strategic growth with a focus on expanding support and capacity for pharmaceutical and biotech clients across the development cycle.
Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates
/PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative...
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the...
Campbell unites pharmaceutical science, clinical research in future-focused degree
The reimagined bachelor’s program prepares students for careers across the entire drug development lifecycle, with an emphasis on hands-on experience… More on this post
COLL Q2 Deep Dive: ADHD Expansion and Pain Business Headwinds Shape Guidance
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 6.3% year on year to $199.9 million. The company’s full-year revenue guidance of $840 million at the midpoint came in 3.4% below analysts’ estimates. Its non-GAAP profit of $1.92 per share was 8.8% above analysts’ consensus estimates.
COLL Q2 Deep Dive: ADHD Expansion and Pain Business Headwinds Shape Guidance
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 6.3% year on year ...
AI generates personalized radiopharmaceutical therapy doses in under 23 seconds
The model has the potential to improve upon the one-size-fits-all dosing approach used for most RPT prostate cancer treatments.
Ocular Therapeutix Reports Second Quarter Revenue, Provides Business Highlights
BEDFORD, Mass.—Ocular Therapeutix, Inc. (NASDAQ: OCUL), an integrated biopharmaceutical company in the retina space, has reported financial results for the second quarter ended June 30, 2026, and provided recent business highlights. Total net revenue was $13.5 million for the second quarter of 2026, flat as compared with the same period in 2025. The company also reported a net loss of $78.8 million for the quarter, compared with a net loss of $67.8 million for the comparable quarter of 2025.
Senate Panel To Examine Biotech's Role in U.S. Health Resilience
Senate Finance Committee investigates biotech's impact on U.S. health resilience as China gains pharmaceutical advantage. Hear expert testimony August 4.
UConn School of Pharmacy and Pharmaceutical Sciences Professor Xiuling Lu Receives Director Promotion
UConn School of Pharmacy and Pharmaceutical Sciences Professor (SoPPS), Xiuling Lu, was recently announced as the new Director of Research and Graduate Educ ...
Twisted laser light can tell mirror-image molecules apart
Scientists have created twisted laser beams that interact differently with right-handed and left-handed molecules, revealing their identity through the fragments they produce. The approach could provide a faster, simpler, and more sensitive way to analyze important molecules used in chemistry and pharmaceuticals.
Industry and D.C. Are Racing Ahead on Psychedelics. They Should Let Science Lead.
President Trump and pharmaceutical companies are betting big on psychedelics. But hype isn't the same as scientific proof, and urgency must be coupled with caution.
GOP firebrand moves to dissolve Congressional Black Caucus: ‘Federally sanctioned segregation’
Nancy Mace's resolution would bar race-based House caucuses, effectively forcing dissolution of the Congressional Black Caucus and similar groups.
Samsung Biologics: geographic diversification is a sound business decision
Samsung Biologics has been on a steep upward growth trajectory since receiving its first licence to produce biologic drug substances in 2015.
Cardinal Health to buy Strive Medical, AdaptHealth's diabetes health business for $360M
Cardinal Health is pursuing two tuck-in acquisitions to expand its home care business. | The pharmaceuticals and specialty products distributor plans to buy AdaptHealth's diabetes health business unit and medical supply provider Strive Medical in separate deals worth $360 million.
Bristol Myers, NVIDIA join forces to build life science’s ‘most powerful’ AI factory
BMS enhances its AI computing power with NVIDIA's DGX SuperPOD as big pharma race to stay competitive within the shifting global landscape.
Nancy Mace passes on Senate bid, cites ‘unfinished business’
The Lowcountry congresswoman had previously run in the GOP gubernatorial race before conceding and endorsing Alan Wilson.
Wooly Mammoth startup Colossal seeking at least $20B valuation
Its research could be foundational in pharmaceuticals, climate change reversal, and longevity.
Bristol Myers Squibb Building Life Science Industry’s Most Advanced AI Factory on NVIDIA Vera Rubin
The pharmaceutical company has demonstrated how AI can transform how drugs discovery and is now scaling AI across R&D to accelerate the discovery of next-generation medicines.
Delivering Access
There was once a time when you healthcare without mentioning Honeybee Health Inc. In 2019, CNBC listed it as one of the 100 most promising startups. In
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing innovative...
Mace says split with Trump ‘may have ended my political career’
Rep. Nancy Mace (R-S.C.) said Monday that her split with President Trump over her push for the Epstein Files Transparency Act could have been the tipping point in her failed gubernatorial bid. “It…
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
/PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has completed the acquisition of...
Pesticide makers stack wins against US environmental, public health groups
The U.S. Supreme Court handed a major legal victory to German agrichemical and pharmaceutical company Bayer last month when it reined in thousands of lawsuits accusing the German company of failing to warn users that glyphosate, the active ingredient in its Roundup weedkiller, causes cancer.
Bayer sells stake in contraceptives business to Apollo in €3bn financing deal
Sale will help German pharmaceuticals group to bolster its balance sheet after years of litigation over Roundup weedkiller
Vertex to buy Crinetics in $10 billion deal
Vertex Pharmaceuticals will buy Crinetics Pharmaceuticals for a total equity value of about $10 billion, the companies said on Monday.
CVS Health Corporation (CVS) Shares Up Significantly After Jim Cramer Said He Was Looking For A Good Year
We recently published Jim Cramer’s Biggest Winners to Buy: Top 20 AI & Other Stocks He Got Right in 2026. CVS Health Corporation (NYSE:CVS) is one of the stocks discussed by Jim Cramer. Pharmaceutical retailer CVS Health Corporation (NYSE:CVS) has become one of Cramer’s top stocks in the sector. Throughout this year, the CNBC TV […]
Anthropic debuts AI-driven pharma R&D tool, Claude Science
Anthropic launches Claude Science as big tech companies increasingly eye expansion in the wider healthcare and life sciences space.
Peptides are the latest US health craze. But what exactly are they?
While peptides are taking the health and wellness category by storm for various use cases, what exactly are they? Leerink Partners senior research analyst Michael Cherny helps break down what a peptides are, how people are choosing them for personal health and recovery reasons, and who the biggest winners in consumer pharmaceuticals could be if their popularity continues to grow.
Indy economic development leaders visiting Switzerland on trade trip
The trip will involve meetings with leaders in the life sciences, biotechnology and pharmaceuticals, medical technology, digital heath and advanced manufacturing sectors.
Databricks and Nvidia Launch Genesis Workbench for AI Scientists
AI is becoming an increasingly important tool for drug discovery. However, for many pharmaceutical and biotech companies, the challenge isn’t finding more powerful models. It’s getting existing models to work […]
Ingredion plans global Benicaros prebiotic expansion across gut and immune health applications
Ingredion highlights that its recent acquisition of the Benicaros prebiotic is a strong strategic addition to its Healthful Solutions portfolio, supporting the company’s formulation versatility alongside expansion of health-forward and clean label ingredients. The company purchased the patented prebiotic fiber, made from upcycled carrot pomace, from NutriLeads earlier this month. With the deal, Ingredion obtained full ownership of all intellectual property, trademarks, human clinical trials, and know-how related to manufacturing Benicaros.
Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial
Positive results from the MULBERRY Phase III trial showed that efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy, demonstrated a statistically significant and clinically meaningful improvement in bone health in children (2 to
Scientists measure hidden quantum forces that could power a new generation of pharmaceutical drugs
It's one thing to design a pharmaceutical drug. It's another to know if and why it actually works; not on paper or in a computer model, but inside the chaotic world of living systems, where proteins twist ...
Scientists measure hidden quantum forces that could power a new generation of pharmaceutical drugs
Researchers invent a laser technique that reveals the hidden forces shaping proteins, advancing a future of precision medicine engineered with quantum precision.
Latest COVID booster may offer bonus health benefit, study suggests
The latest COVID-19 vaccine (2024-2025) has been linked to fewer serious heart-related events among U.S. veterans. New research confirmed a small reduction in COVID-related cardiovascular events, or COVID-19-associated MACE, due to the vaccine.
This health data provider could benefit as AI reshapes drug research
Harvey Stober, senior equity analyst and correspondent at CNBC, explains why this healthcare company could benefit from artificial intelligence reshaping the drug industry thanks to its treasure trove of data.
Scott Lowe, researcher: ‘Governments must fund science. Pharmaceutical companies want to help, but they also want to make money’
The geneticist speaks with EL PAÍS about the advances and challenges in the field of cancer research
Obama Center launch brings Democratic political glitterati to Chicago ahead of crucial elections
Political elites, White House alums, donors and business leaders will converge on Chicago on Thursday to commemorate the launch of the Obama Presidential Center.
Q&A: What does science say about plants as medicine?
Plants have always played an integral role in traditional medicine and healing practices. In this Q&A, Kent Vrana, Elliot S. Vesell Professor of Pharmacology and director of the Center for Cannabis and Natural Product Pharmaceutics at Penn State College of Medicine, discussed the relationship is between plant science and human health and the growing role of plant-derived solutions in medicine.
Our New Study Shows That The Science Of Cannabis And Sleep Extends Beyond THC (Op-Ed)
“We found that the strongest evidence for improving sleep was associated with cannabidiol (CBD), cannabinol (CBN) and combinations of the two—but not primarily THC.” By Andrea Efre, University of South Florida College of Nursing The cannabis sleep market represents a shift away from traditional pharmaceuticals toward a natural alternative. Historically, cannabis products marketed for sleep […]
ECRD 2026: Europe’s rare disease bottleneck is funding rather than science
Derisking assets to attract capital and rethinking funding models should be key priorities for Europe to retain its research pipeline.
House Dems Ilhan Omar and Sarah McBride mock Republican Nancy Mace over gubernatorial primary drubbing
Reps. Ilhan Omar and Sarah McBride mocked Rep. Nancy Mace after she placed fifth in the South Carolina GOP gubernatorial primary contest.
Bayer appoints Reinhard to president of radiology business
Bayer announced that Dr. Jost Reinhard will be appointed president of the radiology business within Bayer’s Pharmaceuticals Division.
Astronauts Could Grow Their Own Medicines in Space Using Plants
The pharmaceutical cabinet of the future might look a lot like a garden.
Nancy Mace's political career is up in the air after finishing last in South Carolina primary
After a decade of roiling South Carolina and national politics, Rep. Nancy Mace finished a distant fifth in her state's Republican primary for governor.
Nancy Mace's unpredictable career is up in the air after finishing last in South Carolina primary
Rep. Nancy Mace has finished a distant fifth in South Carolina's Republican primary for governor, leaving her political future uncertain.
Three of four Republicans who forced the release of the Epstein files are now out of jobs
With GOP Rep. Nancy Mace’s embarrassing fifth-place finish in the South Carolina gubernatorial primary Tuesday, three of the four House Republicans who forced the release of the Jeffrey Epstein files will soon no longer hold elected office.
Once a rising star, Nancy Mace suffers resounding defeat in governor’s race
The South Carolina congresswoman finished fifth in the state’s GOP gubernatorial primary, according to unofficial returns, solidly losing even her own home county and district.
Navy Admiral Fired by Hegseth Advances to Runoff to Replace Mace
Nancy Lacore would face a tough fall election in a district drawn in 2021 to be more Republican. She is seeking to replace Representative Nancy Mace, who ran unsuccessfully for governor instead of running for re-election.
US: Global Health Aid Tied to Harmful Conditions
The United States government is conditioning lifesaving health assistance on broad access to surveillance data and extractive rights to pathogen samples and data for pharmaceutical development.
Scientists achieve the first total synthesis of a complex alkaloids isolated from plant
Monoterpenoid indole alkaloids (MIAs) are plant-derived molecules with unique pharmaceutical potential, but their highly complex and intricate structures make them difficult to produce in the laboratory. Now, researchers from Japan have developed a new strategy that enables the total synthesis of bisleuconothine A and bousigonine B, two biologically relevant oligomeric MIAs. Their findings lay the foundation for further studies of this family of molecules. Monoterpenoid indole alkaloids (MIAs) are plant-derived molecules with unique pharmaceutical potential, but their highly complex and intricate structures make them difficult to produce in the laboratory. Now, researchers from Japan have developed a new strategy that enables the total synthesis of bisleuconothine A and bousigonine B, two biologically relevant oligomeric MIAs. Their findings lay the foundation for further studies of this family of molecules.
Rep. Mace: If price of an endorsement was ‘to not vote to release the Epstein files, that is a price I am unwilling to pay.’
WATCH: Mace says Trump's endorsement hasn't sealed SC gubernatorial race: ‘It’s a dog fight’
Rep. Nancy Mace says Trump's endorsement of Lt. Gov. Pamela Evette hasn't resonated with grassroots Republicans in South Carolina's GOP primary.
Nancy Mace knows her Epstein vote screwed her with Trump. She doesn’t care.
In her run for South Carolina governor she’s battling several controversies and headwinds — including the president endorsing her opponent.
U.S. Supreme Court sides with generic drug maker for severe hypertriglyceridemia agent icosapent ethyl
The decision clears the way for Hikma Pharmaceuticals' sale of icosapent ethyl in the U.S. market.
E-bike safety; lung cancer treatment and prevention; keeping CMA Festival attendees safe; plus other stories with Vanderbilt Health sources
WKRN News 2 interviewed Jeffrey Upperman, MD, FACS, Professor and Chair of the Department of Pediatric Surgery and Surgeon-in-Chief of Monroe Carell Jr. Children’s Hospital at Vanderbilt, about e-bike related injuries following the recent death of a Brentwood High student and a proposal to require safety training before students could ride a bike on a school campus in Williamson County. Fabien Maldonado, MD, MSc,Professor of Medicine and Thoracic Surgery, was on WTVF News Channel 5‘s live studio show, “Openline,” with host Ben Hall, to discuss lung cancer, treatment and prevention. WSMV’s “Today In Nashville” program hosted Vanderbilt LifeFlight paramedic/flight nurse practitioner Tony Smith to talk about safety for the CMA Festival. The New York Times reporter Carl Zimmer interviewed James Crowe, MD, Director of the Vanderbilt Center for Antibody Therapeutics, for a story about the race to find vaccines and treatments as Ebola spreads. The Vanderbilt Health News release about the pilot clinical trial conducted by Vanderbilt Health and Cumberland Pharmaceuticals Inc., that confirms the safety of ifetroban and supports the further development of the drug to prevent cancer metastasis, was picked up by Reuters, Stock Titan,and others. Women We Admire has named Lee Ann Liska, President and Chief Operating Officer, to its list of top women leaders of Nashville for 2026. Radiology Business, Aunt Minnie, Bioengineer, and Imaging Technology News covered the study from Consuelo Wilkins, MD, MSCI, the Mildred Thornton Stahlman Professor in Rural Health and professor of Medicine in the Division of Geriatric Medicine, that found Black and Hispanic people, while known to be far more apt to have dementia, are significantly less apt than other racial and ethnic groups to show Alzheimer’s pathology on brain scans. STAT News interviewed Deva Sharma, MD, Transfusion Medicine & Hematology-Oncology, for a story about more patients requesting unvaccinated blood and what it means for the medical system at large. Yahoo! Health reporter Korin Miller interviewed Gitanjali Srivastava, MD, Director of Obesity Medicine, for a story about how semaglutide and tirzepatide compare. William Schaffner, MD, Professor of Preventive Medicine, was quoted by several news outlets about public health issues, including: NBC News (new COVID vaccinations); Medscape (pneumonia and sepsis); and CNN (protection from contagious viruses). Shelbyville Times-Gazette is repurposing Jessica Pasley’s July 2025 Vanderbilt Health News story on tick-borne illnesses as a front-page story.
UNT Health Fort Worth’s new pharmaceutical sciences program comes at ‘critical time’ for region
Starting this fall, UNT Health Fort Worth will offer a new pharmaceutical sciences PhD program — the first of its kind in North Texas. The school said the new program could help address workforce needs as the life sciences and research and development industries continue to grow in the region.
UNT Health Fort Worth’s new pharmaceutical sciences program comes at ‘critical time’ for region
Starting this fall, UNT Health Fort Worth will offer a new pharmaceutical sciences PhD program — the first of its kind in North Texas. The school said the new program could help address workforce needs as the life sciences and research and development industries continue to grow in the region.
UNT Health Fort Worth’s new pharmaceutical sciences program comes at ‘critical time’ for region
Starting this fall, UNT Health Fort Worth will offer a new pharmaceutical sciences PhD program — the first of its kind in North Texas. The school said the new program could help address workforce needs as the life sciences and research and development industries continue to grow in the region.
Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas
Eli Lilly's new top dealmaker explains how the company changed its approach to M&A now that it's the most valuable pharmaceutical company in the world.
Servier to buy Edgewise's muscular dystrophy business for $2.65bn
Servier has signed an agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in a deal valued at up to $2.65bn.
Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business
/PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has entered into an agreement to...
Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
Three Monarchs Earn Prestigious National Science Foundation Graduate Research Fellowships
By Robyn Sidersky Three recent Old Dominion University graduates are preparing to tackle some of society’s biggest scientific challenges, from developing sustainable pharmaceuticals to restoring wetlands and advancing regenerative medicine, with help from one of the nation’s most prestigious graduate fellowships.
Croma Skincare – Where Science Meets Skin
LEOBENDORF, Austria, May 26, 2026--With Croma Skincare, Austrian family-owned company Croma Pharma translates decades of expertise in aesthetic medicine into a modern skincare line designed for everyday results. Rather than following short-lived trends, Croma focuses on scientifically proven ingredients and pharmaceutical-grade formulations that deliver visible performance while fitting seamlessly into daily routines.
Why Big Business Loves Costly Regulations
In new research, Luca Macedoni and Ariel Weinberger argue that large firms are more likely to lobby in favor of strict industry regulations when they can reduce competition by imposing high fixed costs on smaller, less-profitable firms.
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification
Anavex Life Sciences Corp. (“Anavex” or the “Company”)(Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, today announced it received anexpected delinquency notification letter (the “Notice”) from the Listing QualificationsDepartment of The Nasdaq Stock Market LLC (“Nasdaq”) on May 20, 2026.
World Health Assembly endorses resolution on precision medicine
At the Seventy-ninth World Health Assembly, Member States endorsed a new resolution on Precision medicine: a path towards targeted, personalized and equitable care, taking an important step towards advancing precision medicine as part of efforts to strengthen equitable, effective and sustainable health systems. Precision medicine refers to the use of clinical, molecular, genomic and other health data to inform prevention, diagnosis and treatment, taking into account variability while applying appropriate ethical and legal safeguards. When integrated responsibly into health systems, precision approaches can improve outcomes across different disease areas and across the life course – from cancer and rare diseases to infectious diseases, maternal, newborn and child health, mental health and noncommunicable diseases. The resolution reflects rapid advances in genomics, diagnostics, data science and digital health, alongside widening global inequities in access to these innovations. Many populations – particularly in low- and middle-income countries – remain underrepresented in data and research, limiting the public health impact of precision medicine and risking the widening of health disparities if action is not taken now. "Precision medicine is not an aspirational idea for health delivery in the future – it is already transforming lives across the world. But its benefits remain out of reach for too many and the research driving progress is concentrated in high income countries. This WHA resolution gives global health leaders, ministries of health, and WHO a clear mandate: to act. From infant screening to setting up genomic databases WHO will work with countries to bring about the power of these innovations." Dr Meg Doherty, Director Science for HealthThrough the resolution, Member States commit to developing and strengthening national policies, infrastructure, workforce capacity and governance frameworks to support the safe, ethical and equitable integration of precision medicine into health systems, aligned with universal health coverage. This includes promoting affordability, ensuring inclusive research and data systems, strengthening regulation and data governance, and fostering collaboration across sectors and regions.WHO is requested to provide technical and normative support, review and coordinate existing guidance, facilitate global and regional collaboration, and develop a Global Strategy on Precision Medicine to guide equitable and context‑appropriate implementation. WHO stands ready to support Member States through tools such as a country maturity model for countries to self-assess capacity in implementing precision medicine depending on their context. In the immediate term WHO will map all existing guidance and frameworks and host extensive consultations with interest holders globally.By placing equity, inclusion and public value at the centre of precision medicine, the resolution reinforces WHO’s commitment to ensuring that scientific advances benefit all people, everywhere, and that no one is left behind in the next era of health innovation."By uniting people-centered healthcare with innovation, precision medicine has the potential to transform lives. This resolution helps ensure those advances serve the shared goal of health for all." Dr Sylvie Briand, Chief Scientist For further information please visit the Health Topic: Genomics
The Science Behind the Quest for a Non-Peptide Oral Weight Loss Drug
Not only does it have a tongue-twisting name, “orforglipron” has a complex molecular structure that made its synthesis very challenging. A massive effort by chemists at the Eli Lilly pharmaceutical
Health Care Roundup: Market Talk
Find insight on AstraZeneca, Sino Biopharmaceutical, ConvaTec and more in the latest Market Talks covering the Health Care sector.
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
NORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on devel...
Mace targets Squad Dem with proposed constitutional ban on foreign-born lawmakers
Rep. Nancy Mace proposes expanding the natural-born citizen requirement beyond the presidency to Congress, federal judges and cabinet appointees.
Goalkeeper Macey to leave Colchester
Colchester United goalkeeper Matt Macey is among four first team players released by the club.
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
/PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc....
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
KFF Poll Finds That Most Adults Lack Confidence in Key Health Agencies to Act Independently — The Monitor
KFF’s latest Health Tracking Poll finds that confidence in the independence of key government health agencies overseeing food and drug safety and public health is low among the public and across partisans. Most of the public also share a distrust of agriculture, food, and pharmaceutical companies to act in the public’s best interest, compared with doctors and health care providers who are much more trusted among the public.
‘I support redistricting’: Rep. Nancy Mace says the White House provided South Carolina GOP with new Congressional map
Precigen Reports First Quarter 2026 Financial Results and Business Updates
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced first quarter 2026 financial results and business updates.
Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates
/PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative...
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing medicines that target the melanocortin receptor (MCR) system, today announced financial results for its fiscal third quarter ended March 31, 2026, and provided a business update.
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
MOUNTAIN VIEW, Calif., May 13, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended March 31, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates.
Health Care Roundup: Market Talk
Find insight on the deal between Hengrui Pharmaceuticals and Bristol Myers Squibb and more in the latest Market Talks covering the health care sector.
Bayer Profit Up On Seed Business But Glyphosate Sales Struggle
German agrichemical and pharmaceutical giant Bayer reported a bump in first-quarter profit on Tuesday, driven by its agricultural business, even as sales of controversial glyphosate-based weedkillers struggled.
Avalere Health expands to Japan with a full-service Advisory, Medical, and Marketing offering, led by industry veteran Junji Yokokawa
Avalere Health, a global strategic partner for the healthcare industry, today announces the launch of its Japan office. The move marks a significant expansion of Avalere Health's global footprint, and the launch of a new strategic offering is designed to support Japanese biopharmaceutical companies end-to-end across the product lifecycle.
Germany’s Healthcare Reforms Herald More Pain for Big Pharma
Donald Trump’s push to bring down drug prices in the US has rattled the world’s leading pharmaceutical companies. Now, they’re confronting a new menace as Germany seeks to plug a ballooning deficit in its public health-insurance funds.
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026Reported glioblastoma (GBM) data showing ~97% improvement in progression-free survival vs. standard-of-care; updated median overall survival (mOS) data to be presented at ASCO 2026Hosting R&D Day on May 21, 2026 in New York City NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and γδ
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
/PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
UToledo Unveils Online Master’s Degree Focused on Health Outcomes and Analytics
The 100% online graduate program equips healthcare professionals with cutting-edge, in-demand analytical skills.
White House says Trump's deals with pharmaceutical companies offer billions in savings
WASHINGTON (AP) — White House economists estimate that President Donald Trump’s deals with pharmaceutical companies to drop some of their U.S. prescription drug prices to what they charge in other countries could save $529 billion over the next 10 years. The analysis obtained by The Associated Press includes the first economy-wide projections behind a policy at the core of Trump’s pitch to voters going into November’s midterm elections for control of the House and Senate.
With Sanford out, who are top contenders to succeed Mace in SC’s 1st district
The winner of the November election will succeed U.S. Rep. Nancy Mace, who is running for governor of South Carolina.
Newly released documents reveal more than $300,000 in taxpayer-funded sexual harassment settlements involving lawmakers
Taxpayers have paid more than $300,000 in confidential sexual harassment settlements on behalf of six former members of the House of Representatives or their offices, according to GOP Rep. Nancy Mace and documents reviewed by CNN.
Fast 15: Justin Macedo - Talk Business & Politics
Justin Macedo was 23 when he purchased the outdoor retail business he had joined the day after graduating from Farmington High School. He started at Uncle Sam’s Safari Outfitters in...
Global Health & WASH: May 2026 Funding Opportunities (14 new opportunities!)
The May update for Global Health & WASH brings new calls that cluster around three distinct shifts: LMIC research leadership moving from funder encouragement into a hard eligibility constraint, pharmaceutical and corporate-linked funders running structurally independent education and use-inspired research portfolios at substantial scale, and AI adoption shifting decisively from speculative tool to operational capability across health and WASH systems alike. In LMIC Research Leadership as Eligibility, Not Encouragement, Wellcome anchors the dominant signal of the month with three separate major calls that all require or strongly center LMIC leadership in their basic eligibility architecture. Wellcome’s ESIC Hubs (£1.5-£1.9M per hub over 3-5 years) explicitly requires an LMIC-based lead applicant, treating Global South leadership as a design constraint rather than a participation goal. Wellcome’s Infectious Disease Clinical Trial Development Award funds transdisciplinary teams whose lead must be a mid-career or established researcher based at an organization in Africa, South Asia, or Southeast Asia. Wellcome’s larger Infectious Disease Clinical Trial Award (£1M-£8M for optimizing licensed interventions) requires the administering organization to be in eligible LMIC regions and at least 50% of applicants based there. Around Wellcome, the same pattern shows up at smaller scale and across funders: CHINNOVA channels $1M into West and Central African research institutions for climate-health work; IBRO’s Neuroscience Training Grants explicitly tier ceilings by region of residence with Africa receiving the highest amount ($5,000); IHME’s GBD Emerging Researcher Award reserves at least one of its two annual awards for an LMIC researcher; Sidaction’s HIV Cure call funds research teams across France, the Netherlands, and eligible African countries with a minimum two-country collaboration requirement. Taken together, these calls signal a meaningful shift in how research equity is being operationalized — not as encouragement language at the bottom of a call, but as a structural feature of who can lead, where the work must be administered, and what proportion of the team must be regionally rooted. In Pharma-Funded Independent Medical Education and Use-Inspired Research, the lineup this month is unusually deep. Pfizer alone runs four parallel calls under independent education and quality improvement frameworks: a Migraine and Women’s Health RFP (200K x 2-year, $500K pool), Migraine IME ($200K, $1M pool), JAK Inhibitor evidence-based education ($100K), and Maternal Vaccination HCP Education in Saudi Arabia ($75K), plus a separate Pediatric Pneumococcal Surveillance research call in Saudi Arabia ($400K per project). Novo Nordisk Foundation runs four parallel calls of its own at substantial scale: Infectious Diseases Catalyst Grants (DKK 60M pool, up to DKK 7M collaborative), Non-Diabetic Endocrinology Collaborative Grants (DKK 53M pool, DKK 5-10M per project), Pioneer Innovator Grant Health (DKK 1.1M), and Distinguished Innovator Grant Health (DKK 6.8M). LEO Foundation deploys DKK 2-4M per project for dermatology research excellence. Pfizer’s framing across calls deliberately separates the funding from product promotion, emphasizing measurable practice-relevant change and structural distance between scientific outputs and commercial activity. Novo Nordisk’s “use-inspired” hard filter pushes researchers toward a credible translation pathway from mechanism to deployable tool. The pattern: industry-aligned funders are running structurally independent portfolios at meaningful $ that fund implementation evidence, not promotion. In AI as Operational Capability, Not Speculation, several calls this month explicitly treat AI adoption as a near-term operational question with real evidence and governance requirements, rather than a speculative trend to be watched. Wellcome’s ESIC Hubs frames AI as “the accelerator” for evidence synthesis, asking hubs to translate technical innovation into adoption-ready workflows that can match real-world policy timelines. UNICEF Venture Fund’s new Climate Tech for Children’s Health call funds for-profit startups deploying AI, machine learning, and blockchain in low-resource environments, with a strict requirement that solutions must already have a working prototype with promising pilot results. The Water Research Foundation has launched two simultaneous AI calls treating reproducibility, cybersecurity guardrails, and human-in-the-loop deployments as core design constraints rather than nice-to-haves: one on GenAI and Agentic AI in water utilities ($200K), one on alternatives to water shutoffs that explicitly screens for implementation economics evidence. Nordic Innovation’s quantum technology call (NOK 4.5M) extends the same logic into life science and healthcare, demanding consortium-stage projects mature enough to test with real users. TEF-Health offers €300K in subsidized testing infrastructure for European healthcare AI and robotics SMEs. The pattern: funders are converting AI pilots into playbooks, requiring transfer evidence and risk controls before AI can move from experimentation to sector-wide operational practice. For LMIC-based researchers in infectious disease or evidence synthesis, the three Wellcome calls together represent the deepest concentration of LMIC-led research capital in recent memory — pair the Infectious Disease Clinical Trial Development Award (£200K, deadline May 19) as a strategic pipeline feeder into the larger Infectious Disease Clinical Trial Award (£1-£8M, deadline June 2), since the development award functions explicitly as a track into the larger trial scheme. For Nordic researchers, the four Novo Nordisk Foundation calls plus LEO Foundation and Nordic Innovation Quantum represent ~$30M in regional research capital this cycle, all with deadlines clustered in May-August. For WASH practitioners, the three Water Research Foundation calls together (each up to $200K) are a cluster worth reading across — one on AI deployment, one on shutoff alternatives, one rewarding applied innovation — and the strongest applicants will articulate how their work bridges utility operations to policy-relevant evidence. For US-based clinical researchers and educators, the four Pfizer calls plus the APF Portfolio’s 80+ programs form an unusually accessible recurring pipeline; APF’s prohibition on indirect costs is a meaningful structural feature for early-career applicants whose institutions might otherwise absorb significant overhead. Snapshot of New Opportunities Total Estimated Funding Pool: $100 Million+ USD The grants are organized into three categories: Open Calls: Current grant and opportunities with a deadline. Grants are listed by closing date. 39 open opportunities- 14 new! Rolling Applications: current grant and opportunities with rolling applications (but it’s still best to submit as early as possible). 14 rolling opportunities- 1 new opportunity! Long term planning: Grants that have closed their current rounds, but are expected to open new windows. 4 long term opportunities! A quick tip for returning readers: if you want to jump straight to the newest additions, use CTRL F to search for “New!” and navigate quickly to the latest funding opportunities This post is for paid subscribers. This helps support the time and effort it takes to curate and organize these opportunities. Subscribe To keep this accessible to everyone who needs it, we’re happy to offer pay what you can rates. You can find more details here. Open Calls: Migraine Competitive Grant Program: Migraine and Women’s Health (Quality Improvement and/or Research RFP), Pfizer.*Closing soon!* Pfizer, in collaboration with the American Headache Society, is seeking independent quality improvement and research projects that close persistent gaps in migraine care for women across the United States. The funding logic centers on measurable, practice-relevant change: proposals should generate actionable evidence, tools, or system improvements that can be shared and used widely, not just within a single site. Priority areas span menstrual migraine and screening in women’s health settings, the role of hormonal fluctuations across the lifespan, sex-specific risk factors, comorbidities and quality-of-life burden, and disparities in outcomes by race, ethnicity, and socioeconomic status. The call is structured as a two-step competitive process with an initial Letter of Intent, with the strongest concepts expected to translate scientific insight into implementable improvements in diagnosis, management, and equity. Geographies: United States. Who can apply: U.S.-based organizations (not individuals), including professional schools, healthcare institutions, professional organizations, and other entities focused on healthcare improvement. Funding amount: Up to USD $200,000 total over 2 years; total pool USD $500,000. Targeted Sectors / SDGs: Health; Focus areas: migraine, women’s health, quality improvement, clinical research, menstrual migraine, health disparities. Deadline: LOI: May 5, 2026; Full proposal (by invitation): August 28, 2026. Learn more and apply here. This RFP rewards “shareable impact”: the most competitive submissions will pair rigorous methods with a clear plan for system uptake and dissemination beyond the originating institution. ReSSARC: Strengthening the Health Sector and Food Security in the Central African Republic (AID 013381/01/0) Call for Proposals, Italian Agency for Development Cooperation (AICS). *Closing soon!* AICS is seeking a limited set of high-capacity humanitarian partners to deliver an integrated package that stabilizes essential health services while reducing acute malnutrition and strengthening food security resilience in priority areas of the Central African Republic. The funder’s logic is explicitly nexus-based: proposals should meet urgent, life-saving needs while reinforcing local systems, coordination mechanisms, and community-level capacity so results persist beyond the emergency window. AICS emphasizes inclusion and protection outcomes, expecting gender-sensitive design and explicit measures for groups facing compounded vulnerability, including women, children under five, internally displaced people, and people with disabilities. The call also signals a localization pathway, encouraging stronger collaboration with national NGOs and balanced partnerships, alongside clear coordination with existing cluster and humanitarian actors to minimize duplication and improve coverage. Geographies: Central African Republic (Bangui, Ombella-Mpoko, Ouham, Ouham-Pende, Lim-Pende, Lobaye). Who can apply: Non-profit organizations registered with AICS, plus eligible non-profits without an office in Italy that have a pre-existing collaboration agreement with an AICS-listed organization. Funding amount: Total pool EUR €1,800,000; max EUR €800,000 (single applicant) or EUR €1,000,000 (ATS). Targeted Sectors / SDGs: Health; Focus areas: malnutrition prevention and treatment, maternal and child health, community health services, food security and resilience, localization partnerships Deadline: May 5, 2026. Learn more and apply here. This call is structured to reward partners who can link frontline service delivery to system durability and localization, not just short-term coverage gains. Contracts for Innovation in drug and alcohol addiction healthcare, Innovate UK. *Closing soon!* Innovate UK, on behalf of the Office for Life Sciences Addiction Healthcare Goals program, is procuring R&D to accelerate innovations that can improve treatment outcomes, strengthen recovery, and reduce harm and deaths linked to drug and alcohol addiction. The competition is positioned as a market-facing readiness push: selected projects are expected to advance solutions toward later-stage validation, generate evidence of user acceptability and UK market fit, and map credible routes through regulatory and certification requirements. Innovate UK signals a preference for innovations that can be field-tested in relevant UK settings and progressed to TRL 6 or 7, with practical plans for commercialization after contract completion. This structure favors applicants that can execute most work in-house, co-develop with service providers and people with lived experience, and translate technical progress into deployable tools for addiction healthcare delivery. Geographies: United Kingdom. Who can apply: Single organizations of any size (including EU, EEA, or international) leading delivery, with most work and key deliverables carried out in the UK; subcontractors for specialist skills only. Funding amount: GBP £200,000–1.5 million per project (inclusive of VAT); Total pool: GBP £20 million (across two strands). Targeted Sectors / SDGs: Health; Focus areas: Mental Health, Health Systems Strengthening, Research & Development, Technology Access. Deadline: May 6, 2026 (11:00am). Learn more and apply here. This call uses procurement to pull near-market addiction innovations toward operational proof and adoption pathways in UK services.
Binghamton student finds her purpose inside and outside the classroom
Through a Binghamton University public health class and pharmaceutical internship, Camil Ventura ’26 found her calling.